191 results for "SAAG, KENNETH G."
Showing 1–20 · 1.11 seconds · RSS
-
Journal Article Full text
GLUCOCORTICOIDS IN CHRONIC DISEASE: THE GOOD, THE BAD, THE BONE
Despite the advent of more targeted therapies, glucocorticoids (steroids) remain in chronic use (defined as > 3 months or more) by an estimated 0.5% of the population. Steroids yield symptomatic benefits for systemic and local inflammation as well as disease-modifying properties in rheumatoid…
-
Journal Article Full text
Prevention and Treatment of Bone Changes Associated with Exposure to Glucocorticoids
Rheumatologic diseases are associated with a pro-inflammatory state which is thought to lead to many of the bone changes seen in treatment-naive patients. However, glucocorticoids remain a common treatment option for rheumatologic diseases and are known to have a negative impact on bone through…
-
Journal Article Full text
Epidemiology, risk factors, and lifestyle modifications for gout
Gout affects more than 1% of adults in the USA, and it is the most common form of inflammatory arthritis among men. Accumulating data support an increase in the prevalence of gout that is potentially attributable to recent shifts in diet and lifestyle, improved medical care, and increased…
-
Journal Article Full text
Progress in osteoporosis and fracture prevention: focus on postmenopausal women
In the past decade, we have witnessed a revolution in osteoporosis diagnosis and therapeutics. This includes enhanced understanding of basic bone biology, recognizing the severe consequences of fractures in terms of morbidity and short-term re-fracture and mortality risk and case finding based on…
-
Journal Article Full text
Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis
Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with…
-
Journal Article Full text
Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
INTRODUCTION: Gout is a common and disabling cause of arthritis in middle-aged and elderly populations, with its main predisposing factor being hyperuricemia (serum urate > 6.8 mg/dL). Options for treatment of chronic gout until 2008 were allopurinol, a xanthine oxidase inhibitor, and the group of…
-
Journal Article Full text
Serum urate, menopause, and postmenopausal hormone use: from eminence to evidence-based medicine
The relationship between serum urate, menopause, and aging has not been clearly defined by scientific evidence. In the present issue of Arthritis Research and Therapy, Hak and Choi present a cross-sectional analysis to clarify the effect of menopause and hormone replacement therapy on serum urate…
-
Journal Article Full text
Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy
INTRODUCTION: Glucocorticoid-induced osteoporosis is an underrecognized complication of chronic glucocorticoid therapy characterized by a decrease in new bone formation. Anabolic therapies, such as teriparatide, a recombinant human parathyroid hormone, combat the disease by promoting new bone…
-
Journal Article Full text
Osteoporotic fractures in older adults
Osteoporotic fractures are emerging as a major public health problem in the aging population. Fractures result in increased morbidity, mortality and health expenditures. This article reviews current evidence for the management of common issues following osteoporotic fractures in older adults…
-
Journal Article Full text
Healthcare Providers' Recommendations for Physical Activity among US Arthritis Population: A Cross-Sectional Analysis by Race/Ethnicity
INTRODUCTION: We examined racial/ethnic disparities in healthcare providers' recommendations for physical activity among individuals with arthritis and evaluated this association among groups of individuals who adhered to physical activity guidelines and those who did not. METHODS: With a…
-
Journal Article Full text
Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice
Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis. To date, six large randomized controlled clinical trials on the efficacy of pharmaceutical treatment in GIOP have been conducted. All of these studies have focused predominately on bone mineral density…
-
Journal Article Full text
Improving drug adherence in osteoporosis: an update on more recent studies
Similar to other chronic diseases such as diabetes and hypertension, osteoporosis has struggled with suboptimal medication adherence, resulting in an increased risk of fractures and all-cause mortality. The goal of this narrative review was to summarize interventions to improve medication adherence…
-
Journal Article Full text
Long-term Safety Concerns of Antiresorptive Therapy
Bisphosphonates prevent the loss of bone mineral content by inhibiting bone resorption. As a result, bone turnover is decreased and bone mineral density maintained or even increased. Currently, bisphosphonates account for approximately 80% of all medications prescribed for osteoporosis.(1) Although…
-
Journal Article Full text
Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in the national Veterans Administration gout cohort
OBJECTIVE: To assess factors associated with the ability to achieve and maintain target serum urate (SU) with allopurinol in patients with gout. METHODS: We used National VA national databases from 2002-2012. Eligible patients had ≥1 inpatient or ≥2 outpatient visits with a diagnostic code for…
-
Journal Article Full text
Mortality and osteoporotic fractures: is the link causal, and is it modifiable?
Osteoporosis is a global problem with an expected increase in f acture prevalence and public health burden as the world s population ages. Although excess mortality is well-described in those with low bone mineral density as well as those with recent hip and vertebral fractures, some uncertainty…
-
Journal Article Full text
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?
An association between high levels of serum urate and cardiovascular disease has been proposed for many decades. However, it was only recently that compelling basic science data, small clinical trials, and epidemiological studies have provided support to the idea of a true causal effect. In this…
-
Journal Article Full text
Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?
-
Journal Article Full text
Is there a role for cherries in the management of gout?
Despite the availability of effective urate-lowering therapy (ULT) and anti-inflammatory drugs for the treatment of gout, there is considerable interest in novel treatment approaches. Patients with gout often have a multitude of comorbidities, leading to concern over drug–drug interactions and…
-
Journal Article Full text
Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithm
Osteoporosis is the most commonly encountered metabolic bone disease, and metabolic bone-disease clinics have been established to assist in the diagnosis and treatment of uncommon causes of low bone-mineral density. Hypophosphatemia leading to metabolic bone disease may be encountered, and an…